578 related articles for article (PubMed ID: 31101403)
1. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
Allegretti AS; Zhang W; Zhou W; Thurber TK; Rigby SP; Bowman-Stroud C; Trescoli C; Serusclat P; Freeman MW; Halvorsen YC
Am J Kidney Dis; 2019 Sep; 74(3):328-337. PubMed ID: 31101403
[TBL] [Abstract][Full Text] [Related]
2. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.
Halvorsen YC; Walford GA; Massaro J; Aftring RP; Freeman MW
Diabetes Obes Metab; 2019 Nov; 21(11):2496-2504. PubMed ID: 31297965
[TBL] [Abstract][Full Text] [Related]
3. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
Dagogo-Jack S; Pratley RE; Cherney DZI; McGuire DK; Cosentino F; Shih WJ; Liu J; Frederich R; Mancuso JP; Raji A; Gantz I
BMJ Open Diabetes Res Care; 2021 Oct; 9(1):. PubMed ID: 34620621
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
[TBL] [Abstract][Full Text] [Related]
5. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
[TBL] [Abstract][Full Text] [Related]
6. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
7. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
Dholariya S; Dutta S; Singh R; Parchwani D; Sonagra A; Kaliya M
Expert Opin Pharmacother; 2023; 24(18):2187-2198. PubMed ID: 37817422
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Yamout H; Perkovic V; Davies M; Woo V; de Zeeuw D; Mayer C; Vijapurkar U; Kline I; Usiskin K; Meininger G; Bakris G
Am J Nephrol; 2014; 40(1):64-74. PubMed ID: 25059406
[TBL] [Abstract][Full Text] [Related]
9. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.
Xie L; Han J; Cheng Z; Liu D; Liu J; Xu C; Sun W; Li Q; Bian F; Zhang W; Chen J; Zhu Q; Thurber TK; Lock JP; Zhang B
J Diabetes; 2024 Apr; 16(4):e13526. PubMed ID: 38584148
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Fioretto P; Del Prato S; Buse JB; Goldenberg R; Giorgino F; Reyner D; Langkilde AM; Sjöström CD; Sartipy P;
Diabetes Obes Metab; 2018 Nov; 20(11):2532-2540. PubMed ID: 29888547
[TBL] [Abstract][Full Text] [Related]
12. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen YD; Lock JP; Zhou W; Zhu F; Freeman MW
Diabetes Obes Metab; 2019 Oct; 21(10):2248-2256. PubMed ID: 31161692
[TBL] [Abstract][Full Text] [Related]
13. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Sato K; Miyakawa M; Tamura K; Kanamori A
J Diabetes Investig; 2021 Aug; 12(8):1408-1416. PubMed ID: 33377605
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
Diabetes; 2021 Jan; 70(1):1-16. PubMed ID: 33106255
[TBL] [Abstract][Full Text] [Related]
16. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
Grunberger G; Camp S; Johnson J; Huyck S; Terra SG; Mancuso JP; Jiang ZW; Golm G; Engel SS; Lauring B
Diabetes Ther; 2018 Feb; 9(1):49-66. PubMed ID: 29159457
[TBL] [Abstract][Full Text] [Related]
17. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
[TBL] [Abstract][Full Text] [Related]
18. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
[TBL] [Abstract][Full Text] [Related]
19. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
20. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Cao H; Rao X; Jia J; Yan T; Li D
Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]